{"id":56000,"date":"2023-04-19T15:03:04","date_gmt":"2023-04-19T13:03:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/"},"modified":"2023-04-19T15:03:04","modified_gmt":"2023-04-19T13:03:04","slug":"nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/","title":{"rendered":"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Data showcased the mechanism of action, design, and delivery of NTX-250 in preclinical studies<\/i><\/li>\n<li>\n<i>Coupling cell signaling components with local delivery of NTX-250 resulted in robust anti-tumor activity, as evidenced in murine models<\/i><\/li>\n<li>\n<i>Collaborative study between Nutcracker Therapeutics and the research groups at UCSF presented as late-breaking oral abstract<\/i><\/li>\n<\/ul>\n<p>EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nutcrackerx.com%2F&amp;esheet=53383398&amp;newsitemid=20230419005192&amp;lan=en-US&amp;anchor=Nutcracker+Therapeutics&amp;index=1&amp;md5=71dee0e46ead41ef21b88c6e59be65b6\" rel=\"nofollow noopener\" shape=\"rect\">Nutcracker Therapeutics<\/a>, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company\u2019s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/5\/Nutcracker_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/21\/Nutcracker_Logo.jpg\"><\/a><\/p>\n<p>\nThe lead indication for NTX-250 is cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection, which can progress to cervical cancer if left untreated. More than 90 percent of cervical cancer and CIN cases are linked to HPV infection, with HPV16 as the most prevalent high-risk strain.<\/p>\n<p>\nNutcracker\u2019s poster presentation #5163 outlined how NTX-250 stimulates an immune response to clear HPV-driven tumors in murine models via the synergistic interactions between its three RNA-encoded protein components \u2014 the HPV16 E6 and E7 antigens, and immunomodulators IL-12 and LIGHT \u2014 which are delivered locally into the tumor as a single mRNA drug product.<\/p>\n<p>\nThis study confirmed the advantages of intratumoral over intramuscular delivery of NTX-250, finding that intratumoral delivery provided robust tumor infiltration of antigen-specific T cells. This resulted in turning the \u201ccold\u201d tumors \u201chot,\u201d by simultaneously lowering the immunosuppressive effects of the tumor microenvironment and stimulating antigen-specific T cells to clear the tumor. Notable takeaways from the data include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nComplete tumor regression and long-term, recurrence-free survival in all 10 tumor-challenged mice intratumorally administered with NTX-250<\/li>\n<li>\nNo tumor-free mice in the negative control group or in mice treated intramuscularly with NTX-250<\/li>\n<li>\nIntratumoral injection of NTX-250 resulted in immune cell infiltration and the secretion of proinflammatory Th1\/M1 associated cytokines, which aid in turning \u201ccold\u201d tumors \u201chot\u201d<\/li>\n<\/ul>\n<p>\nFurther, Nutcracker&#8217;s poster presentation #690 described the use of a novel endolysosomal trafficking domain, CD1d, to elicit an improved T cell-mediated adaptive immune response when designing mRNA-based therapies using NTX-250 as an example. Introducing these signaling domains within the drug molecule design can address challenges in antigen presentation and processing by driving specific subcellular localization of antigenic proteins to enhance antigen presentation and the subsequent immune response. Notable takeaways include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAntigens linked to the CD1d endolysosomal trafficking domain showed sustained intracellular expression that resulted in improved CD4 and CD8 antigen-specific engagement<\/li>\n<li>\n<i>In vivo<\/i>, these antigen-CD1d mRNA molecules significantly improved the antigen-specific CD8 T cells responses and enhanced the immunoglobulin response<\/li>\n<\/ul>\n<p>\n\u201cThe latest data represent an important milestone in the growing body of research supporting the therapeutic potency of NTX-250, while validating the biological versatility and clinical potential of mRNA as a modality on the whole,\u201d explained Chief Medical Officer Robert J. Schott, M.D. \u201cWe\u2019ll work diligently to build on these promising results in the ongoing fight to improve outcomes for CIN patients by providing a better alternative to the current surgical standard of care.\u201d<\/p>\n<p>\nAdditionally at AACR, a late-breaking oral presentation was given, discussing data from a collaborative study between Nutcracker and the research groups of Drs. Lawrence Fong and David Oh at the University of California, San Francisco \u2014 which mapped shared tumor antigen reactivity using nanoparticle-encapsulated mRNA in prostate cancer patients.<\/p>\n<p>\n\u201cAs Nutcracker continues to harness the unique characteristics of mRNA to treat a broad range of oncology indications, this recent preclinical achievement further supports our efforts to deliver on the modality\u2019s clinical promise to patients,\u201d remarked Chief Executive Officer Igor Khandros, Ph.D. \u201cBeyond our pipeline, Nutcracker\u2019s proprietary RNA design, delivery, and manufacturing platform is also positioned to play a crucial role in streamlining the development of new RNA medicines.\u201d<\/p>\n<p>\nThe data presented at the AACR Annual Meeting build upon <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nutcrackerx.com%2Fnews-overview%2Fpress-releases%2Fpress-detail%2F%3Fpress_id%3D1963&amp;esheet=53383398&amp;newsitemid=20230419005192&amp;lan=en-US&amp;anchor=previously+presented+preclinical+data&amp;index=2&amp;md5=f16522e74ad1d60fd04a4bb8e93f83a6\" rel=\"nofollow noopener\" shape=\"rect\">previously presented preclinical data<\/a> on the viability of this mRNA composition as a therapeutic. NTX-250 is expected to enter Phase I clinical trials by early 2024.<\/p>\n<p>\n<b>About Nutcracker Therapeutics, Inc.<\/b><\/p>\n<p>\nNutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker\u2019s technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.<\/p>\n<p>\nFor more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nutcrackerx.com&amp;esheet=53383398&amp;newsitemid=20230419005192&amp;lan=en-US&amp;anchor=www.nutcrackerx.com&amp;index=3&amp;md5=c2f06ecf916be498230363232a8a6d65\" rel=\"nofollow noopener\" shape=\"rect\">www.nutcrackerx.com<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nGeir Falck-Pedersen<br \/>\n<br \/>HDMZ<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#x3a;&#x6e;u&#116;&#99;&#x72;&#x61;c&#107;&#x65;&#x72;p&#114;&#x40;&#x68;d&#109;&#122;&#x2e;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x4e;&#117;&#116;c&#x72;&#x61;&#99;k&#x65;&#x72;&#112;r&#x40;&#x68;&#100;m&#x7a;&#x2e;&#99;o&#x6d;<\/a><br \/>(312) 506-5244<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data showcased the mechanism of action, design, and delivery of NTX-250 in preclinical studies Coupling cell signaling components with local delivery of NTX-250 resulted in robust anti-tumor activity, as evidenced in murine models Collaborative study between Nutcracker Therapeutics and the research groups at UCSF presented as late-breaking oral abstract EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;Nutcracker Therapeutics, Inc., a &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56000","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Data showcased the mechanism of action, design, and delivery of NTX-250 in preclinical studies Coupling cell signaling components with local delivery of NTX-250 resulted in robust anti-tumor activity, as evidenced in murine models Collaborative study between Nutcracker Therapeutics and the research groups at UCSF presented as late-breaking oral abstract EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;Nutcracker Therapeutics, Inc., a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-19T13:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/21\/Nutcracker_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting\",\"datePublished\":\"2023-04-19T13:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/\"},\"wordCount\":782,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230419005192\\\/en\\\/1584334\\\/21\\\/Nutcracker_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/\",\"name\":\"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230419005192\\\/en\\\/1584334\\\/21\\\/Nutcracker_Logo.jpg\",\"datePublished\":\"2023-04-19T13:03:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230419005192\\\/en\\\/1584334\\\/21\\\/Nutcracker_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230419005192\\\/en\\\/1584334\\\/21\\\/Nutcracker_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting - Pharma Trend","og_description":"Data showcased the mechanism of action, design, and delivery of NTX-250 in preclinical studies Coupling cell signaling components with local delivery of NTX-250 resulted in robust anti-tumor activity, as evidenced in murine models Collaborative study between Nutcracker Therapeutics and the research groups at UCSF presented as late-breaking oral abstract EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;Nutcracker Therapeutics, Inc., a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-19T13:03:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/21\/Nutcracker_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting","datePublished":"2023-04-19T13:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/"},"wordCount":782,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/21\/Nutcracker_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/","name":"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/21\/Nutcracker_Logo.jpg","datePublished":"2023-04-19T13:03:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/21\/Nutcracker_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230419005192\/en\/1584334\/21\/Nutcracker_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nutcracker-therapeutics-demonstrates-immunotherapeutic-potency-of-lead-mrna-candidate-at-the-2023-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56000"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56000\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}